Clinical trial
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral…
NCT00443287 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00443287 |
|---|---|
| Title | Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 Doses of HMR1766 Versus Placebo With Cilostazol as a Calibrator, Administered for 26 Weeks in Patients With Peripheral Arterial Disease (PAD) Fontaine Stage II |
| Acronym | ACCELA |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intermittent Claudication |
| Intervention type | Drug |
| Interventions | ataciguat (HMR1766), placebo, cilostazol |
| Enrollment | 553 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 5, 2007 |
| Last update posted | May 17, 2018 |
| Countries | Austria, Canada, France, Poland, Russia, South Africa, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: